Regulatory approval announcements from health authorities in the respective countries

Gilead Signs Royalty-Free Deals with Six Generics for Investigational HIV Drug Lenacapavir in 120 Countries

Oct 2, 2024, 01:35 PM

Gilead Sciences has signed non-exclusive, royalty-free voluntary licensing agreements with six generic pharmaceutical manufacturers, including Dr. Reddy's Laboratories and Hetero, to enable access to its investigational HIV prevention medication, lenacapavir, across 120 high-incidence, resource-limited countries. Lenacapavir, pending regulatory approval, is a twice-yearly injectable drug used for HIV-1 prevention and treatment in heavily treatment-experienced adults. The agreements aim to increase global access to this groundbreaking medication, accelerating the global HIV response.